Anzeigenschluss: 26.02.2025
Erscheinungstermin: 24.03.2025
Gastroonkologie
Editorial
Young Oncologists United
Gastroonkologie
CRC
Andre T et al.
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
GIST
Blay J-Y et al.
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Ösophaguskarzinom
Jia R et al.
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC):
A Multicenter, Randomized, Open-Label, Phase 3 Trial
CRC
van der Lei S et al.
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
CRC
van der Kruijssen F et al.
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group
Cholangiokarzinom
Fortbildung
Das intrahepatische Cholangiokarzinom als eigenständige Entität
S3-Leitlinie Pankreaskarzinom
Interview
Was bringt das Update Neues?
Kongressbericht
ASCO-GI
Hämatologie
MDS
Della Porta MG et al.
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Multiples Myelom
Dimopoulos M et al.
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Hodgkin Lymphom
Herrera AF et al.
Nivolumab + AVD in Advanced-Stage Classic Hodgkin's Lymphoma
AML
Sobas MA et al.
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
Dermatoonkologie
Melanom
Wolchok JD et al.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Melanom
Li AT et al.
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy
Melanom
Dugas-Breit S et al.
Employment, work ability and sick leave in melanoma patients within the first year of diagnosis
Gynäkoonkologie
Brustkrebs
Schmid P et al.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Zervixkarzinom
Lorusso D et al.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18):
overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Brustkrebs
de Boniface J et al.
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
Sexuelle Gesundheit
Interview
Wichtige Aspekte für die Praxis
Pneumoonkologie
NSCLC
Jänne PA et al.
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
NSCLC
Mok T et al.
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
NSCLC
Pérol M et al.
CNS protective effect of selpercatinib in first-line RET fusion-positive advanced non-small cell lung cancer
Uroonkologie
Prostatakarzinom
Buyyounouskiet MK al.
Noninferiority of hypofractionated vs conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms the NRG-GU003 phase 3 randomized clinical trial
RCC
Allaf ME et al.
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
RCC
Tannir NM et al.
Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: a phase III randomized study (PIVOT-09)
Kongressbericht
ASCO-GU
Supportivtherapie
Tumorkachexie
Arrietta O et al.
Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia:
A Randomized Clinical Trial
CINV
Inui N et al.
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Mukositis
Peng X et al.
Streptococcus salivarius K12 alleviates oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors: a randomized controlled trial
Antiemese
Fortbildung
Prophylaxe und Therapie Tumortherapie-induzierter Nausea und Emesis: Update der MASCC/ESMO-Leitlinie – was ist neu?
Allgemeine Onkologie
CUP-Syndrom
Liu X et al.
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial
Kongressbericht
Update Onkologie
wie wirkt was ...?
BTK-Inhibitoren im Blick
*Die Redaktion behält sich aktuelle Änderungen vor.